Cyclacel Pharmaceuticals Files 8-K
Ticker: BGMSP · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1130166
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: CYCC
TL;DR
Cyclacel filed an 8-K, likely with financial updates. Stay tuned.
AI Summary
On July 15, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Cyclacel Pharmaceuticals, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- 0001130166 (company) — Central Index Key
- 911766850 (company) — I.R.S. Employer Identification Number
- July 15, 2025 (date) — Date of Report
FAQ
What specific information is being disclosed in this 8-K filing?
The filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', but the specific details of the disclosure are not provided in the excerpt.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is July 15, 2025.
What is the Central Index Key (CIK) for Cyclacel Pharmaceuticals, Inc.?
The CIK for Cyclacel Pharmaceuticals, Inc. is 0001130166.
In which state was Cyclacel Pharmaceuticals, Inc. incorporated?
Cyclacel Pharmaceuticals, Inc. was incorporated in Delaware.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).